Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Lawrence M. Alleva net worth and biography

Lawrence Alleva Biography and Net Worth

Director of Mersana Therapeutics

Lawrence M. Alleva has served as a member of our Board of Directors since September 2017. Prior to his retirement in June 2010, Mr. Alleva was employed by PricewaterhouseCoopers LLP for 39 years, including 28 years as a partner. Mr. Alleva served clients primarily in the technology sector, as well as pharmaceutical and biotechnology companies. Additionally, he served in a variety of office and regional practice leadership roles, most recently as ethics and compliance leader (assurance) for PwC from 2006 until his retirement. Mr. Alleva is a Certified Public Accountant (inactive).

Mr. Alleva received a Bachelor of Science degree in accounting from Ithaca College and attended the Columbia University Executive MBA (non-degree) Program. Mr. Alleva also serves as a director for Bright Horizons Family Solutions Inc., Galera Therapeutics Inc. and Adaptimmune Therapeutics plc. He previously served as a director of TESARO, Inc., Mirna Therapeutics, Inc., and GlobalLogic, Inc., and chaired the audit committee for each of those companies.

What is Lawrence M. Alleva's net worth?: The estimated net worth of Lawrence M. Alleva is at least $14,979.20 as of December 1st, 2023. Mr. Alleva owns 9,362 shares of Mersana Therapeutics stock worth more than $14,979 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Alleva may own. Learn More about Lawrence M. Alleva's net worth.
How do I contact Lawrence M. Alleva?: The corporate mailing address for Mr. Alleva and other Mersana Therapeutics executives is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. Mersana Therapeutics can also be reached via phone at (617) 498-0020 and via email at [email protected]. Learn More on Lawrence M. Alleva's contact information.
Has Lawrence M. Alleva been buying or selling shares of Mersana Therapeutics?: Lawrence M. Alleva has not been actively trading shares of Mersana Therapeutics during the last ninety days. Learn More on Lawrence M. Alleva's trading history.
Who are Mersana Therapeutics' active insiders?: Mersana Therapeutics' insider roster includes Lawrence Alleva (Director), Andrew Hack (Director), Timothy Lowinger (Insider), Ashish Mandelia (VP), Anna Protopapas (CEO), and Arvin Yang (Insider). Learn More on Mersana Therapeutics' active insiders.
Are insiders buying or selling shares of Mersana Therapeutics?: During the last twelve months, insiders at the sold shares 9 times. They sold a total of 117,957 shares worth more than $256,846.84. The most recent insider tranaction occured on October, 28th when SVP Mohan Bala sold 1,884 shares worth more than $3,579.60. Insiders at Mersana Therapeutics own 11.8% of the company. Learn More about insider trades at Mersana Therapeutics.
Information on this page was last updated on 10/28/2024.

Lawrence M. Alleva Insider Trading History at Mersana Therapeutics

Lawrence M. Alleva Buying and Selling Activity at Mersana Therapeutics

Mersana Therapeutics Company Overview

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $1.60

$1.56

$1.68

50 Day Range

MA: $2.16

$1.60

$2.68

2 Week Range

Now: $1.60

$1.22

$6.28

Volume

2,724,133 shs

Average Volume

1,583,316 shs

Market Capitalization

$197.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4